Drug intelligence / Profile preview

LBI-001

Development stage: Preclinical
Lead developer: Longevity Biomedical
Modality: Small Molecules
Administration: Intravenous

Overview

LBI-001 is an investigational therapy developed by Longevity Biomedical for the treatment of retinal vein occlusion (RVO), a chronic eye condition characterized by the formation of small blood clots in the veins that drain blood from the retina. The therapeutic approach combines intravenous administration of microspheres with non-invasive ultrasound, aiming to improve retinal blood flow and address vision loss associated with RVO[1][2].

Beyond the preview

Go deeper on LBI-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LBI-001.

Explore the full profile